




RealRate

PHARMACEUTICAL 2021

Edesa Biotech Inc.
Rank 285 of 409



Edesa Biotech



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Edesa Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edesa Biotech Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Edesa Biotech Inc. is the variable Net Income, reducing the Economic Capital Ratio by 156% points.

The company's Economic Capital Ratio, given in the ranking table, is -253%, being 102% points above the market average of -355%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 8,104 |
| Cost of Goods Sold | 18 |
| Intangible Assets | 2,484 |
| Liabilities, Current | 1,530 |
| Liabilities, Non-Current | 94 |
| Other Assets | 160 |
| Other Compr. Net Income | 55 |
| Other Expenses | 0.80 |
| Other Liabilities | 30 |
| Other Net Income | 37 |
| Property and Equipment | 15 |
| Research and Development | 3,329 |
| Revenues | 329 |
| Selling, General and Administrative Expense | 3,383 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 10,762 |
| Liabilities | 1,654 |
| Expenses | 6,730 |
| Stockholders Equity | 9,108 |
| Net Income | -6,364 |
| Comprehensive Net Income | -6,337 |
| Economic Capital Ratio | -253% |